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Psoriasis is a genetic disorder of the skin causing inflammatory disease, characterized by increased squamous cell proliferation and impaired differentiation. The CARD14 gene was recently identified as the first gene directly linked to Psoriasis [1] . It is reported that more than 15 mutations and some polymorphisms are associated with the disease [2] . 1,25(OH) 2 D 3 is the endogenously produced, hormonally active form of vitamin D 3 . In addition to the known effect of 1,25(OH) 2 D 3 on controlling calcium and bone metabolism, it inhibits proliferation and induces terminal differentiation of cultured human keratinocytes. It can also modulate the immune system in a variety of ways, enhancing immunosuppressive and anti-inflammatory pathways, which are its possible mechanisms of action in psoriasis lesions. Serum Vit D 3 levels can be low in psoriasis patients due to some extrinsic factors such as dietary or geographically low sun exposure. However, decreased levels of Vit D 3 are not caused by vitamin D deficiency [3] [4] [5] [6] . 1,25(OH) 2 D 3 elicits its action on target tissues through the vitamin D receptor (VDR). The receptor-hormone complex binds to hormone response elements in regulatory regions of target genes, and modulates the gene transcription. However, it has been noted that cultured fibroblasts and keratinocytes from some psoriatic patients have partial resistance to 1,25(OH) 2 D 3 -mediated anti-proliferative activity [6, 7] . Although therapeutic efficacy of 1a,25-dihydroxyvitamin D 3 [1,25(OH) 2 D 3 ] and its analogues have been tested and proved to be effective for the treatment of psoriasis [8] , clinical response to 1,25(OH) 2 D 3 treatment is variable in patients [9] . Experiments examining the anti-proliferative effects of calcitriol demonstrated that about 25% of psoriatic patients possessed dermal fibroblasts that exhibited partial resistance to calcitriol [7] . The gene encoding the VDR is known to contain a number of polymorphisms. A polymorphic start codon in the 5' end of the gene is identified by the restriction enzyme FokI. In the 3' end of the gene, there are 3 polymorphisms generating BsmI, ApaI and TaqI restriction sites [10] . Molecular studies have shown that certain VDR polymorphisms could be associated with bone mineral density, hyperparathyroidism, osteomalacia, insulin-dependent diabetes mellitus, osteoarthritis, and some malignancies such as breast and prostate carcinoma [10] [11] [12] [13] [14] . However, a number of negative and positive associations in different populations have been reported. Genetic polymorphism of the VDR gene may influence 1,25(OH) 2 D 3 -mediated normal physiologic response of keratinocytes and can explain the variable responsiveness. In this study, we aimed to compare the allele and genotype frequencies of VDR genotypes and haplotypes in psoriasis patients and healthy controls, and to determine the association between VDR polymorphism and response to vitamin D therapy.
Material and Methods

Patients
A total of 102 psoriasis patients (47 women and 55 men) and 102 controls (50 women and 52 men) were enrolled in this study. Psoriasis patients were diagnosed clinically and/or histopathologically. All the patients were clinically evaluated concerning their family history of psoriasis, nail involvement, psoriatic arthralgia, and psoriasis area and severity index. Following a 2-week wash-out period during which no systemic or topical treatments were used, 50 patients were prescribed calcipotriol ointment and/or scalp solution and asked to apply the medication over the plaques twice daily for 6 weeks. The clinical response was assessed by psoriasis area and severity index (PASI). Patients were then grouped into 2 categories: non-responders (defined as improvement less than 50%) and responders (defined as improvement more than 50%) [15] .
The protocol for this study was approved by the ethics committee of the Pamukkale University, Medical Faculty. Written informed consent was obtained from all volunteers.
VDR genotype analysis
The genotype for 4 SNPs of the VDR gene was determined by the digestion pattern of the amplified DNA fragments using the restriction enzymes Apa I, Bsm I, Fok I and Taq I. Blood samples were collected into K3EDTA-tubes and stored at -20°C. DNA was extracted from whole blood by a salting out procedure [16] . Genomic DNA was amplified by PCR using specific primers as previously described: for Apa I and Taq I primer-1, 5'-CAGAGCATGGACAGGGAGCAA-3'; primer-2, 5'-GCAACTCCTCATGGCTGAGGTCTC-3' [17] ; for Bsm I primer-3, 5'-CAACCAAGACTACAAGTACCGC GTCAGTGA-3'; primer-4, 5'-AACCAGCGGGAAGAGGTC AAGGG-3' [18] ; for Fok I primer-5, 5'-AGCTGGCCCTGGC ACTGACTCTGCTCT-3'; primer-6, 5'-ATGGAAACACCTTG CTTCTTCTCCCTC-3' [19] . PCR was performed in a volume of 50 µl with 100 ng sample DNA, 200 µM dNTPs, 10 pmol of each primer, 1.5 mM MgCl 2 , 1XPCR buffer and 1 U Taq DNA polymerase (MBI Fermentas, Lithuania). PCR products were amplified in a programmable thermal cycler (Hybaid-PCRSprint, Middlesex, UK). The PCR conditions were 5 min at 94°C for initial denaturation, 30 sec at 94°C, 30 sec at 60°C for Apa I, Taq I, Fok I, 65°C for Bsm I, 30 sec at 72°C, 30 cycles, followed by 5 min at 72°C for final extension. Specific PCR products were obtained 740 bp, 265 bp and 825 bp for Apa I and Taq I, Fok I and Bsm I, respectively. PCR products were digested with the restriction enzymes Apa I, Taq I, Bsm I (Mva1269I) and Fok I (BseGI) (MBI Fermentas, Lithuania) according to the manufacturer's instructions, and electrophoresed on 1.4% or 1.7% agarose gels (Prona, Spain). For both BsmI and FokI, Apa I, and Taq I genotypes were defined by capital letters in the absence of the restriction site (A, B, F, T, respectively) and small letters where the restriction site was present (a, b, f, t, respectively).
Haplotype and statistical analysis
Allele frequencies were calculated from genotype frequencies based upon Hardy-Weinberg equilibrium; p, q: allele frequency, p2, q2, 2pq: genotype frequency.
Haplotype analysis was done by CHAPLIN1.2 [20] . Differences in the VDR allele and genotype frequency were compared between psoriasis patients and controls by significance test between percentages. One-way analysis of variance was used to compare clinical parameters with genotypes. The P value less than 0.05 was regarded as statistically significant, and analysis was carried out by SPSS9.0. This may be confirmed by studying interaction and activity characteristics of VDR protein in these subjects. In addition, transcriptome results, which were provided by Jordan et al.
[2], can give some clues about the starting point.
Morrison et al. in 1992 [18] reported that the b allele tends to decrease VDR mRNA expression. Chen et al. in 1996 [33] reported that VDR expression has been induced in psoriatic lesion of patients who received vitamin D, indicting that vitamin D 3 induced the expression of VDR mRNA in responders but not in non-responders. They suggested that the medication played a role in regulation of epidermal keratinocytes and fibroblast proliferation, or in some other way affected lymphocyte migration and proliferation in psoriatic lesions. It is remarkable that Apa I polymorphisms A, and in some cases T (Taq I), are often reported in association with psoriasis. The mechanism of vitamin D 3 therapy and the cause of the resistance in some patients still remain unclear. The Apa I polymorphisms are in the intronic site of the gene, and its importance may be explained by introns playing a role in control of expression through RNA editing and alternative splicing. In conclusion, the findings indicate that VDR polymorphisms may affect response to vitamin D 3 therapy and onset of psoriasis.
conclusions
The number of markers used for genetic association studies are increasing rapidly. After the SNPs era, the copy number variations became very popular and useful in these days, as well junk DNA imminent will become. Genotype analysis has been used for a long time. However, haplotype analysis has recently become important due to the newly developed bioinformatics packets. Every haplotype can be used for creation of haploblocks and tagging. In the view of VDR and psoriasis, only 2 haplotypes were found, including this study. We believe that every association found makes great contribution to our understanding of the resistance to vitamin D 3 therapy in psoriasis. These data can be clarified by the structure-function and binding characteristics studies of the related VDR protein. 
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